Enhabit (NYSE:EHAB) Earns "Sell (D-)" Rating from Weiss Ratings

Key Points

• Enhabit received a "Sell (D-)" rating from Weiss Ratings while UBS Group lowered its price target from $10.00 to $8.50, now rating it as "neutral."
• The company's stock has seen a 2.2% increase and has a current price of $8.55, with an average target price of $8.67 among analysts.
• Insider activity includes CFO Ryan Solomon purchasing 10,000 shares at an average price of $7.64, increasing his ownership in the stock by 5.45%.

Enhabit (NYSE:EHAB - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by equities research analysts at Weiss Ratings in a research note issued to investors on Friday,Weiss Ratings reports.

Separately, UBS Group reduced their price target on shares of Enhabit from $10.00 to $8.50 and set a "neutral" rating on the stock in a research report on Friday, August 8th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $8.67.

Enhabit Stock Up 2.2%

Shares of NYSE EHAB opened at $8.55 on Friday. Enhabit has a one year low of $6.47 and a one year high of $10.90. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.57 and a quick ratio of 1.57. The firm's 50 day simple moving average is $8.04 and its two-hundred day simple moving average is $8.34. The stock has a market capitalization of $433.15 million, a P/E ratio of -3.20 and a beta of 1.69.

Enhabit (NYSE:EHAB - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.13 EPS for the quarter, beating analysts' consensus estimates of $0.10 by $0.03. Enhabit had a negative net margin of 12.84% and a positive return on equity of 2.72%. The business had revenue of $266.10 million for the quarter, compared to analysts' expectations of $263.39 million. As a group, analysts expect that Enhabit will post 0.22 EPS for the current fiscal year.

Insider Activity

In other news, CFO Ryan Solomon bought 10,000 shares of the business's stock in a transaction dated Friday, August 8th. The shares were purchased at an average price of $7.64 per share, for a total transaction of $76,400.00. Following the completion of the acquisition, the chief financial officer owned 193,468 shares of the company's stock, valued at approximately $1,478,095.52. This trade represents a 5.45% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 3.40% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in EHAB. Iron Triangle Partners LP bought a new position in shares of Enhabit in the first quarter worth approximately $10,021,000. 8 Knots Management LLC lifted its stake in Enhabit by 12.6% in the first quarter. 8 Knots Management LLC now owns 4,988,718 shares of the company's stock worth $43,851,000 after acquiring an additional 557,820 shares during the period. Phocas Financial Corp. purchased a new stake in Enhabit in the second quarter worth $3,094,000. Arrowstreet Capital Limited Partnership lifted its stake in Enhabit by 96.5% in the second quarter. Arrowstreet Capital Limited Partnership now owns 640,074 shares of the company's stock worth $6,170,000 after acquiring an additional 314,401 shares during the period. Finally, Nuveen LLC purchased a new stake in Enhabit in the first quarter worth $1,773,000.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.